Phase I Clinical Trial of GPC2 Chimeric Antigen Receptor T (GPC2-CAR T) Cells for Relapsed or Refractory Medulloblastoma in Children and Young Adults is a PHASE1 clinical asset sponsored by Stanford University in Medulloblastoma, Central Nervous System Embryonal Tumor, Refractory Medulloblastoma, Recurrent Medulloblastoma, Pediatric Brain Tumor, Embryonal Tumor With Multilayered Rosettes (ETMR), Pineoblastoma, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS, CNS Neuroblastoma, FOXR2-activated. SEO and diligence focus: GPC2-CAR T cells, Fludarabine, Cyclophosphamide, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.